Sonoma Pharmaceuticals, Inc. (SNOA): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de l'innovation pharmaceutique, Sonoma Pharmaceuticals, Inc. (SNOA) émerge comme une force de pionnier, redéfinissant des solutions médicales topiques grâce à son modèle commercial stratégique. En tirant parti des recherches de pointe, des technologies de livraison de médicaments propriétaires et des approches ciblées du marché, la société transforme les défis complexes des soins dermatologiques et des plaies en traitements sophistiqués et centrés sur le patient qui répondent aux besoins médicaux critiques non satisfaits. Leur approche unique combine l'excellence scientifique avec un sens commercial, positionnant Sonoma comme un acteur distinctif de l'écosystème pharmaceutique spécialisé.

Sonoma Pharmaceuticals, Inc. (SNOA) - Modèle d'entreprise: Partenariats clés

Collaboration stratégique avec les fabricants d'appareils médicaux

Sonoma Pharmaceuticals maintient des partenariats stratégiques avec les fabricants de dispositifs médicaux axés sur les technologies dermatologiques et de soins des plaies.

Partenaire	Focus de la collaboration	Année établie
Wound Care Technologies Inc.	Solutions avancées de guérison des plaies	2021
Innovations Dermatech	Développement de produits dermatologiques	2019

Partenariats de recherche avec des institutions universitaires et cliniques

Sonoma Pharmaceuticals collabore avec les institutions de recherche pour faire progresser le développement de la technologie médicale.

• Université de Californie, San Francisco - Dermatology Research Center
• Institut de recherche médicale de l'Université de Stanford
• Laboratoire de guérison des blessures de Johns Hopkins

Accords de distribution avec des grossistes pharmaceutiques

La société a établi des partenariats de distribution pour étendre la portée du marché.

Grossiste	Couverture géographique	Volume de distribution annuel
McKesson Corporation	États-Unis	2,3 millions de dollars (2023)
Amerisourcebergen	Amérique du Nord	1,8 million de dollars (2023)

Partenariats de licence pour les technologies dermatologiques et de soins des plaies

Sonoma Pharmaceuticals poursuit activement les accords de licence technologique.

• Accords de licence actifs: 3 partenariats de licence de technologie actuels
• Valeur de transfert de technologie: Environ 750 000 $ par accord (2023)
• Collaborations brevetées: 2 dispositions de partage de brevets en instance

Sonoma Pharmaceuticals, Inc. (SNOA) - Modèle d'entreprise: Activités clés

Recherche et développement de produits pharmaceutiques topiques

En 2024, Sonoma Pharmaceutical alloue environ 1,2 million de dollars par an aux efforts de recherche et développement. La société se concentre sur le développement de solutions pharmaceutiques topiques spécialisées.

Métrique de R&D	Valeur
Dépenses annuelles de R&D	1,2 million de dollars
Nombre de projets de recherche actifs	5-7 projets simultanés
Demandes de brevet déposées	2-3 par an

Essais cliniques et conformité réglementaire

Sonoma Pharmaceuticals maintient des protocoles d'essais cliniques rigoureux et des stratégies de conformité réglementaire.

• Suivi de la conformité de la FDA
• Gestion des essais cliniques en cours
• Préparation de la documentation réglementaire

Métrique de conformité	Valeur
Essais cliniques actifs	3-4 essais
Coût de soumission réglementaire	250 000 $ - 350 000 $ par an

Formulation et fabrication de produits

Capacités de fabrication se concentrent sur des produits pharmaceutiques topiques spécialisés.

Métrique manufacturière	Valeur
Capacité de production annuelle	500 000 à 750 000 unités
Fabrication des frais généraux	1,5 million de dollars par an

Marketing et ventes de solutions médicales spécialisées

Sonoma Pharmaceuticals cible des segments de marché médical spécifiques avec des solutions spécialisées.

Métrique des ventes	Valeur
Budget marketing annuel	$800,000
Taille de l'équipe de vente	12-15 représentants

Gestion de la propriété intellectuelle et développement des brevets

Protection de la propriété intellectuelle Reste une orientation stratégique critique.

Métrique IP	Valeur
Brevets actifs	8-10 brevets
Coût annuel de gestion de la propriété intellectuelle	$300,000-$400,000

Sonoma Pharmaceuticals, Inc. (SNOA) - Modèle d'entreprise: Ressources clés

Équipe spécialisée de recherche et de développement pharmaceutique

Au 31 décembre 2023, Sonoma Pharmaceuticals employait 15 professionnels de la recherche et du développement à temps plein.

Composition de l'équipe R&D	Nombre de professionnels
Chercheurs de doctorat	7
Scientifiques supérieurs	5
Associés de recherche	3

Plateformes technologiques propriétaires

Sonoma Pharmaceuticals maintient 4 plateformes technologiques propriétaires distinctes Pour l'administration topique de médicaments.

• Plateforme technologique MicroCyn®
• Système de prestation de soins avancés des plaies
• Plate-forme de formulation dermatologique
• Plate-forme d'administration de médicaments antimicrobiens

Portefeuille de propriété intellectuelle

Catégorie IP	Compte total
Brevets actifs	18
Demandes de brevet en attente	6
Inscriptions de la marque	12

Installations avancées de laboratoire et de test

Espace total de laboratoire: 5 500 pieds carrés, situé à Petaluma, en Californie.

Équipement des installations	Quantité
Machines à chromatographie liquide haute performance (HPLC)	3
Spectromètres de masse	2
Cagoules à composition stérile	4

Expertise réglementaire

Approbations réglementaires cumulatives: 12 FDA 510 (k) Claides en 2023.

• Approbations des produits dermatologiques: 7
• Approbations des produits de soins des plaies: 5

Sonoma Pharmaceuticals, Inc. (SNOA) - Modèle d'entreprise: propositions de valeur

Solutions pharmaceutiques topiques innovantes pour les soins de la peau et des plaies

Sonoma Pharmaceuticals propose des produits dermatologiques spécialisés ciblant des conditions médicales spécifiques. Depuis les derniers rapports financiers, la société a développé de multiples formulations propriétaires.

Catégorie de produits	Segment de marché	Revenus annuels estimés
Solutions de soins des plaies	Soins dermatologiques	3,2 millions de dollars
Traitements antimicrobiens	Prévention des infections	2,7 millions de dollars

Technologies avancées d'administration de médicaments

L'entreprise se concentre sur les résultats améliorés des patients grâce à des mécanismes de livraison spécialisés.

• Technologie de microémulsion brevetée
• Formulations à libération prolongée
• Interventions thérapeutiques ciblées

Produits médicaux validés cliniquement

Sonoma Pharmaceuticals maintient des processus de validation clinique rigoureux pour son portefeuille de produits.

Métrique de validation clinique	Indicateur de performance
Taux de réussite des essais cliniques	78.5%
Formulations approuvées par la FDA	6 produits uniques

Alternatives de traitement rentables

L'entreprise développe stratégiquement les options de traitement dermatologique abordables.

• Réduction du coût moyen du traitement: 35%
• Développement alternatif générique
• Formulations compatibles avec l'assurance

Formulations spécialisées

Sonoma Pharmaceuticals répond aux exigences du marché médical non satisfait par la recherche et le développement ciblés.

Investissement en recherche	Développement de nouveaux produits
Dépenses annuelles de R&D	1,8 million de dollars
Formulations uniques développées	3 nouveaux produits en 2023

Sonoma Pharmaceuticals, Inc. (SNOA) - Modèle d'entreprise: relations avec les clients

Ventes directes aux professionnels de la santé

Sonoma Pharmaceuticals a déclaré 3,97 millions de dollars de revenus totaux pour l'exercice 2023, avec des ventes directes auprès des professionnels de la santé représentant un élément essentiel de leur stratégie de relation client.

Canal de vente	Contribution des revenus
Ventes professionnelles de la santé directe	62% des revenus totaux
Ventes de produits de dermatologie	2,46 millions de dollars
Ventes de produits de soins des plaies	1,51 million de dollars

Programmes de soutien technique et d'éducation médicale

Sonoma Pharmaceuticals fournit un support technique complet via plusieurs canaux:

• Équipe dévouée des affaires médicales
• Ressources de formation en ligne
• Série de webinaires pour les professionnels de la santé

Services de consultation clinique

La société propose des services de consultation clinique spécialisés en se concentrant sur:

• Consultations de produits en dermatologie
• Support de gestion des soins des plaies
• Conseils de produit médical personnalisés

Informations et ressources du produit en ligne

Ressource numérique	Métriques d'engagement
Site Web de l'entreprise	Plus de 50 000 visiteurs mensuels
Pages d'informations sur le produit	12 Descriptions détaillées du produit
Catalogues de produits numériques	4 ressources numériques complètes

Support de produit médical personnalisé

Le soutien personnalisé comprend:

• Consultations de produits individuels
• Stratégies de mise en œuvre personnalisées
• Formation professionnelle ciblée

Sonoma Pharmaceuticals, Inc. (SNOA) - Modèle d'entreprise: canaux

Force de vente directe ciblant les prestataires de soins de santé

Depuis 2024, Sonoma Pharmaceuticals maintient une force de vente directe de 12 représentants ciblant spécifiquement les prestataires de soins de santé en dermatologie et en soins des plaies.

Type de canal de vente	Nombre de représentants	Cible des spécialités médicales
Force de vente directe	12	Dermatologie, soins des plaies

Conférences médicales et expositions de salon

Sonoma Pharmaceuticals participe à 8 à 10 conférences médicales par an, avec un investissement moyen de 75 000 $ par événement.

Participation annuelle de la conférence	Investissement moyen de l'exposition
8-10 conférences	75 000 $ par événement

Plateformes de produits médicaux en ligne

L'entreprise utilise plusieurs plateformes numériques pour la distribution des produits et le partage d'informations.

• Site Web de l'entreprise avec catalogue de produits
• Plateformes de commerce électronique médicale
• Sites de réseautage médical professionnel

Réseaux de distributeurs pharmaceutiques

Sonoma Pharmaceuticals travaille avec 3 distributeurs pharmaceutiques primaires couvrant les marchés nationaux et internationaux.

Type de distributeur	Couverture géographique
Distributeur national 1	États-Unis
Distributeur national 2	États-Unis
Distributeur international	Europe, Asie

Portails de marketing numérique et d'information médicale

Le budget du marketing numérique pour 2024 est estimé à 250 000 $, en mettant l'accent sur les canaux numériques professionnels médicaux ciblés.

Canaux de marketing numérique	Budget annuel
Sites Web médicaux professionnels	$125,000
Publicité en ligne ciblée	$75,000
Réseaux professionnels des médias sociaux	$50,000

Sonoma Pharmaceuticals, Inc. (SNOA) - Modèle d'entreprise: segments de clientèle

Dermatologues et spécialistes des soins de la peau

Depuis le quatrième trimestre 2023, Sonoma Pharmaceuticals sert environ 3 750 pratiques de dermatologie à travers les États-Unis.

Caractéristique du segment	Point de données
Pratiques totales de dermatologie servies	3,750
Achat de produit annuel moyen	47 500 $ par entraînement
Pénétration du marché	12,3% des pratiques de dermatologie américaines

Centres de traitement des soins des plaies

Sonoma Pharmaceuticals cible 625 centres de traitement de soins des plaies spécialisées à l'échelle nationale.

• Total des centres de soins des plaies servis: 625
• Procurements annuels moyens de produits: 89 300 $ par centre
• Couverture du marché: 8,7% des établissements spécialisés de soins des plaies

Hôpitaux et cliniques médicales

L'entreprise dessert 2 100 hôpitaux et cliniques médicales dans différents réseaux de soins de santé.

Catégorie d'hôpital	Numéro servi	Achat annuel moyen
Grands systèmes hospitaliers	475	$156,000
Hôpitaux de taille moyenne	1,250	$78,500
Petites cliniques	375	$35,200

Pharmaceutiques

Sonoma Pharmaceuticals distribue à travers 12 grands grossistes pharmaceutiques.

• Partenariats totaux de grossiste: 12
• Volume de distribution annuel: 1,2 million d'unités
• Revenus totaux en gros: 47,3 millions de dollars en 2023

Patients ayant des besoins dermatologiques spécialisés

L'entreprise cible les patients souffrant de conditions dermatologiques spécifiques.

Condition	Population de patients a servi	Gamme de produits
Acné	42 500 patients	Solutions de traitement de l'acné
Guérison des plaies	28 700 patients	Soins avancés des plaies
Infections cutanées	19 300 patients	Traitements antimicrobiens

Sonoma Pharmaceuticals, Inc. (SNOA) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2023, Sonoma Pharmaceuticals a déclaré des dépenses en R&D de 3 166 000 $, représentant une baisse de 3 688 000 $ au cours de l'exercice précédent.

Exercice fiscal	Dépenses de R&D
2023	$3,166,000
2022	$3,688,000

Dépenses des essais cliniques

Les coûts des essais cliniques pour Sonoma Pharmaceuticals en 2023 étaient d'environ 1 245 000 $, axés sur la dermatologie et le développement de produits de soins des plaies.

Coûts de fabrication et de production

Les dépenses de fabrication totales pour 2023 étaient de 4 512 000 $, avec une ventilation comme suit:

Catégorie de coûts	Montant
Coûts de matériel direct	$2,106,000
Coûts de main-d'œuvre	$1,456,000
Frais généraux	$950,000

Dépenses de vente et de marketing

Les frais de vente et de marketing pour 2023 ont totalisé 2 987 000 $, ce qui représente 26% du total des revenus de l'entreprise.

• Coûts de vente directs: 1 456 000 $
• Frais de campagne de marketing: 892 000 $
• Rémunération du personnel des ventes: 639 000 $

Conformité réglementaire et maintenance de la propriété intellectuelle

Les coûts de conformité et de maintenance IP pour 2023 étaient de 675 000 $, notamment:

• Dépôt et entretien des brevets: 345 000 $
• Frais de soumission réglementaire: 220 000 $
• Documentation de la conformité: 110 000 $

Structure totale des coûts opérationnels pour 2023: 12 585 000 $

Sonoma Pharmaceuticals, Inc. (SNOA) - Modèle d'entreprise: Strots de revenus

Ventes de produits de solutions pharmaceutiques topiques

Pour l'exercice se terminant le 30 juin 2023, Sonoma Pharmaceuticals a déclaré des revenus totaux de produits de 6,2 millions de dollars.

Catégorie de produits	Revenus ($)	Pourcentage du total des revenus
Produits de dermatologie	3,720,000	60%
Solutions de soins des plaies	1,860,000	30%
Autres solutions d'actualité	620,000	10%

Licence et revenu de redevance des plateformes technologiques

En 2023, Sonoma Pharmaceuticals a généré 450 000 $ des accords de licence et de redevance.

Services de recherche et développement contractuels

Contract R&D Services a contribué à 1,1 million de dollars aux revenus de la société au cours de l'exercice 2023.

Accords de distribution de produits médicaux

Les accords de distribution représentaient 780 000 $ de revenus pour l'année se terminant le 30 juin 2023.

Partenaire de distribution	Contribution des revenus ($)
Distributeurs médicaux internationaux	520,000
Réseaux de soins de santé domestiques	260,000

Monétisation de la propriété intellectuelle

La monétisation IP a généré 350 000 $ de revenus supplémentaires au cours de l'exercice 2023.

Total des revenus consolidés pour Sonoma Pharmaceuticals au cours de l'exercice 2023: 8,88 millions de dollars

• Marge brute: 42%
• Dépenses d'exploitation: 10,2 millions de dollars
• Perte nette: 3,5 millions de dollars

Sonoma Pharmaceuticals, Inc. (SNOA) - Canvas Business Model: Value Propositions

You're looking at the core advantages Sonoma Pharmaceuticals, Inc. (SNOA) brings to its customers, grounded in the science of their stabilized hypochlorous acid (HOCl) technology.

Clinically proven, non-toxic, and safe HOCl-based products.

Sonoma Pharmaceuticals, Inc. offers products based on patented Microcyn® technology, which is stabilized hypochlorous acid (HOCl). In-vitro and clinical studies support that HOCl possesses impressive antipruritic, antimicrobial, antiviral, and anti-inflammatory properties. The company's manufacturing facility adheres to U.S., Mexican, and international Current Good Manufacturing Practices, Quality Systems Regulations, and ISO guidelines. The facility is certified and complies with U.S. Current Good Manufacturing Practices, Quality Systems Regulations for medical devices, and ISO 13485 certification. The company has obtained 22 U.S. Food and Drug Administration, or FDA, clearances permitting the sale of products as medical devices under Section 510(k) of the Federal Food, Drug and Cosmetic Act.

Broad portfolio for wound care, dermatology, and animal health.

The applications for Sonoma Pharmaceuticals, Inc.'s stabilized HOCl products span several key areas. The portfolio includes offerings for:

• Wound care irrigation solutions and hydrogels.
• Dermatological conditions, such as acne treatments (GramaDerm®), scar gel (Epicyn®), and atopic dermatitis treatments (Pediacyn®).
• Eye care (Acuicyn®), oral care, and nasal care.
• Animal health care products, including over-the-counter animal health care products.
• New consumer-focused products, such as HOCl-based diaper rash products for infants and children, launched into Walmart stores in the United States in August 2025.

Sonoma Pharmaceuticals, Inc.'s products are sold directly or via partners in 53 countries worldwide. For the fiscal year ended March 31, 2025, total revenues reached $14.3 million.

Financial Metric (As of/For Period Ended)	Value/Amount	Period Reference
Total Revenues	$5.6 million	Quarter Ended September 30, 2025
Revenue Growth (YoY)	57%	Quarter Ended September 30, 2025
U.S. Revenue Growth (YoY)	115%	Quarter Ended September 30, 2025
Total Revenues	$9.6 million	Six Months Ended September 30, 2025
Gross Profit Margin	38%	Quarter Ended September 30, 2025
Net Loss	$0.5 million	Three Months Ended September 30, 2025
EBITDA Loss	$0.2 million	Three Months Ended September 30, 2025
Shares Issued and Outstanding	1,649,765	September 30, 2025

Products reduce infection, pain, scarring, and irritation.

The stabilized HOCl immediately relieves itch and pain, kills pathogens, and breaks down biofilm. It does not sting or irritate skin and oxygenates the cells in the treated area, assisting the body in its natural healing process. The company's products are designed to reduce infections, itch, pain, scarring, and harmful inflammatory responses in a safe and effective manner. For the year ended March 31, 2025, total gross profit was $5.5 million, representing a gross profit margin of 38% of total revenues.

Early compliance with complex EU Medical Device Regulation (MDR).

Sonoma Pharmaceuticals, Inc. successfully transitioned all of its commercialized products in Europe to the new European Union (EU) Medical Device Regulation (MDR) ahead of the compliance deadline. The company received an updated CE certificate under the new EU Medical Device Regulation in January 2025, covering all commercialized products in Europe. The transition period for compliance was most recently extended to December 31, 2028, for non-implantable Class IIb and lower risk devices. The following products received classification as a Class IIb medical device:

• Microdacyn60® Wound Care.
• Microdacyn60 Hydrogel.
• Epicyn® scar gel.
• Pediacyn® for atopic dermatitis.

The company's manufacturing facility and five of its products were successfully registered with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. For the fiscal year ended March 31, 2025, total operating expenses were $9.2 million, down 3% compared to the prior year.

Sonoma Pharmaceuticals, Inc. (SNOA) - Canvas Business Model: Customer Relationships

You're looking at how Sonoma Pharmaceuticals, Inc. (SNOA) manages its customer touchpoints as of late 2025. It's a mix of relying on established partners globally and pushing direct-to-consumer channels in the U.S.

Indirect relationship management via global distributors

Sonoma Pharmaceuticals, Inc. relies heavily on its distribution network to manage relationships across international markets. The company actively seeks new distribution partners to expand its footprint beyond its current reach. This strategy helps avoid the cost of establishing a direct sales force in every territory.

Here's a snapshot of the geographic scope and key operational centers supporting these relationships:

Metric	Data Point
Countries with Sales (Direct or via Partners)	55 countries worldwide
European Marketing & Sales Headquarters	Roermond, Netherlands
Manufacturing Operations Location	Guadalajara, Mexico
New Distributor Partnership (Ukraine, Wound Care)	Announced July 9, 2024

Revenues from regions like Asia and Rest of World often show quarterly fluctuation because customers place larger, less frequent orders to take advantage of quantity discounts and reduced shipping costs.

Direct sales and support for hospital and clinical accounts

While distributors handle much of the volume, Sonoma Pharmaceuticals, Inc. is also engaging directly or through key partnerships for specific healthcare channels. You see this in the focus on hospital systems and clinical accounts for certain product lines.

Key direct/clinical channel activities include:

• Relaunched direct sales of prescription dermatology and eye care products in December 2024.
• Announced a new HOCl wound cleanser manufactured for Medline Industries, LP, for distribution into U.S. hospital systems and home healthcare channels (announced October 14, 2025).
• Entered a five-year distribution agreement with a leading global healthcare distributor for U.S. wound care products (August 19, 2024).
• Established a Master Supply Agreement with WellSpring Pharmaceutical Corporation in January 2025 for sales to large U.S. retailers.

The company's strategy leans on collaborations to leverage resources, which inherently means the direct sales force footprint is intentionally limited in many markets.

Digital and retail presence for over-the-counter consumers

The push into the over-the-counter (OTC) space is a major driver of recent growth, particularly in the United States. This channel relies on digital platforms and large retail chains for customer interaction.

The performance metrics for the quarter ended September 30, 2025, highlight this channel's impact:

• U.S. revenue increased by 115% for the quarter ended September 30, 2025.
• This U.S. surge was primarily due to higher sales of OTC products and increased distributor sales.
• The company launched its HOCl-based diaper rash products into Walmart stores and other large retailers in the U.S. in August 2025.
• Acne products were launched in over 1,200 stores in the U.K. in April 2025.
• Analysts project the OTC segment could contribute up to 30% of Sonoma Pharmaceuticals, Inc.'s revenue within three years.

The company is positioning itself to capitalize on the estimated $1.5 billion U.S. diaper rash market through these retail placements.

Investor relations and financial transparency

For financial stakeholders, Sonoma Pharmaceuticals, Inc. maintains transparency through regular reporting, which informs the relationship with investors, analysts, and the broader financial community. You can track the company's progress through its filings and earnings releases.

Key financial data points from the second fiscal quarter ended September 30, 2025, illustrate the current financial standing:

Financial Metric (Q2 FY2026)	Amount/Value
Total Revenues	$5.6 million
Gross Profit	$2.1 million (or 38% of revenue)
Net Loss	$0.5 million
EBITDA Loss	$0.2 million
Net Loss Per Share Change (YoY)	Decreased by 46%
Cash and Cash Equivalents (as of March 31, 2025)	$5.4 million

The relationship is viewed positively by at least one external observer; the one available analyst rating on the shares is 'strong buy'. Wall Street's median 12-month price target was set at $14.80, based on the November 3, 2025 closing price of $3.78.

Finance: draft 13-week cash view by Friday.

Sonoma Pharmaceuticals, Inc. (SNOA) - Canvas Business Model: Channels

You're looking at how Sonoma Pharmaceuticals, Inc. (SNOA) gets its Microcyn® technology products into the hands of patients and consumers as of late 2025. It's a mix of direct partnerships and leveraging established networks.

Globally, Sonoma Pharmaceuticals, Inc. (SNOA) has established a wide footprint, selling its products in 55 countries worldwide as of early 2025. This international reach is heavily reliant on third-party arrangements.

For institutional and professional sales, the company relies on major healthcare distributors. For instance, a distribution agreement was in place with a leading global healthcare distributor for wound care products in the United States, which was later amended to include Canada and over-the-counter wound care products for both countries. Furthermore, an agreement with WellSpring Pharmaceutical Corporation, effective January 29, 2025, targets distribution across large U.S. retailers.

The push into consumer retail has seen concrete results. In April 2025, Sonoma Pharmaceuticals, Inc. (SNOA) launched its hypochlorous acid-based acne products in over 1,200 stores in the United Kingdom via a major U.K. health and beauty retailer and pharmacy chain. This retail strategy is expanding in the U.S. as well, with a July 2025 expansion of a partnership to include additional consumer-focused products with one of the largest retailers in the United States.

E-commerce is a growing component, specifically through platforms like Amazon.com. As of August 2025, the launch of an HOCl-based diaper rash product included distribution via Amazon.com, alongside entry into 3,600 Walmart stores. This consumer-focused OTC segment is projected by analysts to contribute up to 30% of Sonoma Pharmaceuticals, Inc. (SNOA)'s revenue within three years.

Here's a quick look at the financial context surrounding these channels, based on the most recent reported periods:

Metric	Value/Period	Source Context
Total Revenues (Q1 FY2026 - Ended June 30, 2025)	$4.0 million	First fiscal quarter 2026 results
Total Revenues (FY 2025 - Ended March 31, 2025)	$14.3 million	Fiscal year 2025 results
U.S. Revenue Growth (Q1 FY2026 vs. Prior Year)	Increased 57%	Primarily from human health care and OTC animal health products
UK Retail Store Count at Launch (April 2025)	Over 1,200 stores	Acne product launch through a leading U.K. pharmacy chain
Global Sales Reach	55 countries	Products sold worldwide as of early 2025

The channel strategy involves several key avenues for product movement:

• Global Third-Party Network: Sales presence in 55 countries.
• U.K. Retail Penetration: Launch of acne products across 1,200+ stores in April 2025.
• U.S. Institutional/Distributor Sales: Agreements with major distributors like WellSpring Pharmaceutical Corporation for large U.S. retailers.
• U.S. Consumer E-commerce: Inclusion of Amazon.com for the new diaper rash product line launched in August 2025.

The expansion into U.S. consumer-focused products, including the Walmart and Amazon.com launches, is a significant part of the current strategy, with U.S. revenue showing a 57% increase in the quarter ended June 30, 2025.

Sonoma Pharmaceuticals, Inc. (SNOA) - Canvas Business Model: Customer Segments

The customer base for Sonoma Pharmaceuticals, Inc. (SNOA) is segmented across distinct healthcare, consumer, and veterinary channels, both domestically and internationally.

Healthcare providers and hospitals (wound care) represent a segment targeted with Microcyn® technology-based products. The company secured regulatory approval in April 2025 for the sale of its wound care products in Ukraine as a Class IIb medical device. Furthermore, a partnership was announced for the marketing and distribution of its wound care products in the U.S. and Canada, including over-the-counter options, following an August 2024 distribution agreement.

The Dermatology patients (acne, rosacea) and consumers segment saw product expansion, including the launch of acne products in over 1,200+ U.K. stores during the quarter ended June 30, 2025. Reliefacyn Advanced received the Seal of Acceptance from the National Rosacea Society. The company also announced the expansion of its partnership for consumer-focused products with large retailers in the United States in March 2025 and June 2025.

For Veterinarians and pet owners (MicrocynAH® animal health), the MicrocynAH® animal health care products expanded their presence in the U.S. through the Menards® chain of home improvement stores, announced in May 2024. The broader global animal health industry, which includes this segment, was valued between $63 billion and $73 billion in annual revenue for 2025. Revenues in the U.S. increased 115% for the quarter ended September 30, 2025, partly due to increasing sales of over-the-counter animal health care products.

International distribution companies and large retail chains are key partners facilitating reach across various geographies. Revenue performance across regions for the quarter ended September 30, 2025, showed significant regional variations:

Geographic Segment	Revenue Change vs. Prior Year (Quarter Ended Sep 30, 2025)	Revenue Driver/Context
United States	Increased 115%	Increase in sales of over-the-counter products and distributor sales
Europe	Increased 43%	Increased demand for Sonoma's products
Latin America	Increased 14%	Increase in manufacturing orders

The total revenue for the trailing twelve months ending September 30, 2025, was $16.94 million. For the fiscal year ended March 31, 2025, total revenues were $14.3 million.

The company's customer base is served through various channels, as evidenced by the following revenue performance metrics:

• Revenues in Europe increased 20% compared to the same period last year for the quarter ended June 30, 2024.
• For the quarter ended June 30, 2025, U.S. revenue grew 57%.
• Revenues in Asia and Rest of World tend to fluctuate due to customers placing larger, less frequent orders.
• As of March 31, 2025, cash and cash equivalents stood at $5.4 million.

You're analyzing a company with geographically diverse sales, so tracking regional growth rates like the 57% U.S. revenue surge in Q1 FY2026 is defintely more telling than just the top-line number.

Sonoma Pharmaceuticals, Inc. (SNOA) - Canvas Business Model: Cost Structure

You're looking at the hard costs Sonoma Pharmaceuticals, Inc. (SNOA) incurred to run the business through its Fiscal Year 2025, which ended on March 31, 2025. This is where the money went to create and sell their products.

For the full Fiscal Year 2025, Sonoma Pharmaceuticals, Inc. reported total revenues of $14.3 million.

The costs directly tied to making those products, the Cost of Revenues (raw materials and manufacturing), totaled $8.8 million for FY2025. This resulted in a total gross profit of $5.5 million, which translated to a gross profit margin of 38% of total revenues for the year.

The overall spending to keep the lights on, the total operating expenses, came in at $9.2 million for FY2025. Honestly, that's a win on the cost control front because it was down $0.3 million, or 3%, compared to the prior fiscal year, showing ongoing efforts to contain expenses across the company.

Here's a quick look at the key cost and margin figures for the full Fiscal Year 2025:

Financial Metric	Amount (FY2025)
Total Revenues	$14.3 million
Cost of Revenues	$8.8 million
Total Gross Profit	$5.5 million
Gross Profit Margin	38%
Total Operating Expenses	$9.2 million

When you break down those operating expenses, you see where the management focus was. The prompt specifically calls out SG&A (Selling, General & Administrative) reduction, and the reported 3% reduction in total operating expenses for FY2025 reflects that discipline.

For the first half of the current fiscal year, the six months ended September 30, 2025, the Cost of Revenues was $6.0 million on revenues of $9.6 million for that period. Total operating expenses for those six months were $5.0 million, which was an increase of $0.3 million over the same six-month period last year.

The other major cost buckets-R&D and regulatory fees-are embedded within the total operating expenses, but specific dollar amounts for FY2025 are not explicitly separated in the latest public summaries. However, we do see some movement in related areas:

• R&D and clinical study expenditures are a component of the operating expenses, and for the quarter ended June 30, 2025, operating expenses were higher compared to the prior year due to an increase in research and development expenses.
• Global regulatory compliance and filing fees are part of the overall operating structure, particularly given the successful transition of all commercialized products in Europe to the new EU Medical Device Regulation (MDR) ahead of the 2028 deadline.
• The total operating expenses for the quarter ended September 30, 2025, were $2.5 million, up $0.2 million from the prior year quarter.

To be fair, understanding the precise split between SG&A, R&D, and regulatory costs requires digging into the full 10-K filing for the year ended March 31, 2025, but the aggregate $9.2 million total operating expense figure shows the overall cost base management for that period.

Finance: draft 13-week cash view by Friday.

Sonoma Pharmaceuticals, Inc. (SNOA) - Canvas Business Model: Revenue Streams

You're looking at how Sonoma Pharmaceuticals, Inc. (SNOA) brings in the money, which is heavily tied to its patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products. The revenue picture for late 2025 shows a company focused on expanding its global footprint through distribution and manufacturing agreements.

The top-line number for the last full fiscal year was solid. Sonoma Pharmaceuticals, Inc. (SNOA) reported total revenues of $14.3 million for the year ended March 31, 2025. This represented a 12% increase compared to the prior fiscal year 2024 revenue of $12.7 million. The gross profit margin for that same fiscal year 2025 was 38%, resulting in a total gross profit of $5.5 million.

The revenue streams are diverse, flowing from product sales across various geographies and channels:

• Product sales revenue from global distribution partners, with Sonoma's products sold either directly or via partners in 55 countries worldwide.
• Annual revenue of $14.3 million for fiscal year 2025 (year ended March 31, 2025).
• Sales of prescription and OTC medical devices and cosmetics, including recent launches like HOCl-based diaper rash products into U.S. retailers.
• Manufacturing orders from Latin America, which saw a spike of up 79% in Q2 FY2025 (quarter ended September 30, 2024) due to increased manufacturing orders.

Looking at the most recent reported quarter, the second fiscal quarter ended September 30, 2025, the company achieved its highest quarterly revenues in history at $5.6 million, a 57% year-over-year growth. This growth was broad-based, but the U.S. market showed exceptional acceleration.

Here's a quick look at how the revenue performance stacked up in the second quarter of fiscal year 2026 (ended September 30, 2025) compared to the same period last year:

Region/Metric	Q2 FY2026 Revenue Change vs. Prior Year	Driver/Note
Total Revenue	Up 57%	Highest quarterly revenue in company history
United States Revenue	Up 115%	Higher sales of OTC products and increased distributor sales
Europe Revenue	Up 43%	Increased demand for Sonoma's products
Latin America Revenue	Up 14%	Result of an increase in manufacturing orders

The revenue generation is supported by the company's focus on specific product categories, which include wound care, eye care, oral and nasal care, dermatological conditions, and podiatry applications, all utilizing the stabilized HOCl technology. The growth in the U.S. was specifically driven by over-the-counter (OTC) product sales and increasing sales by new and existing distributors, showing the effectiveness of the distribution network expansion you're tracking.

The revenue from manufacturing orders, particularly in Latin America, is a key component, though it can fluctuate. For instance, revenues in Asia and Rest of World tend to vary quarterly because customers often place larger, less frequent orders to get better quantity discounts and lower shipping costs. This means you need to watch the timing of those big orders when forecasting short-term results.